Man Group’s Century Therapeutics IPSC Stock Holding History

Man Group’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,011	Closed	-$79K	–	2027
2023 Q2	$79K	Buy	+25,011	New	+$80.6K	﹤0.01%	1897
2023 Q1	–	Hold	0	–	–	–	2003

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's IPSC Position: Q3 2023 in Review

Man Group sold out of Century Therapeutics (IPSC) in Q3 2023, closing a stake of 25,011 shares — an estimated $79K sold.

Man Group first reported a position in IPSC in Q2 2023 and held it in 1 quarter. The position peaked at $79K in Q2 2023. 55 funds tracked by Wall St. Rank hold IPSC as of Q3 2023.

Man Group reported no remaining Century Therapeutics position as of Q3 2023 after selling out during the quarter.
Man Group sold 25,011 Century Therapeutics shares in Q3 2023, an estimated $79K.
Man Group first reported a position in Century Therapeutics in Q2 2023 and held it in 1 quarter.
Man Group's Century Therapeutics position peaked at $79K in Q2 2023.
55 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.